Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on TradePub.com for readers like you. LEARN MORE
Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the Follow It Assay from the Exactis Trial
Request Your Free Infographic Now:

"Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the Follow It Assay from the Exactis Trial"

Colorectal cancer is the third leading cause of cancer-related deaths. Clinical responses of metastatic colorectal cancer to first-line treatment range from 35 to 60 percent, but even responders inevitably develop therapeutic resistance. Liquid biopsies have become a useful tool in precision medicine for therapy selection and have immense potential as a monitoring tool for the emergence of therapy resistance.

This poster from Canexia Health presents data from a study investigating if longitudinal plasma ctDNA mutation monitoring can aid in predicting clinical progression before standard-of-care CT imaging, with the goal of establishing the Follow It assay as a liquid biopsy tool to assess progression over time in metastatic colorectal cancer patients.


Offered Free by: Canexia Health
See All Resources from: Canexia Health

Recommended for Professionals Like You:

Thank you

This download should complete shortly. If the resource doesn't automatically download, please, click here.

Thank you

This download should complete shortly. If the resource doesn't automatically download, please, click here.

Thank you

This download should complete shortly. If the resource doesn't automatically download, please, click here.